Validation of a formula for predicting daily CD34+ cell collection by leukapheresis

Cytotherapy

Volumn 14, Issue 4, 2012, Pages 461-466

  Rosenbaum, Eric R ^a   O'Connell, Bernadette ^a   Cottler Fox, Michele ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

apheresis; CD34; collection; formula; plerixafor; prediction

Indexed keywords

CD34 ANTIGEN;

ADULT; AGED; ARTICLE; CD34 SELECTION; CELL MOTILITY; CONTROLLED STUDY; DONOR; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; STOMACH CARCINOMA; TESTIS NONSEMINOMA CANCER; VALIDATION STUDY;

EID: 84858626766     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.652733     Document Type: Article

References (14)

1. + cells in multiple myeloma. Ann Hematol 2001;80:592-7. (Pubitemid 33061999)
2. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33: 907-12. (Pubitemid 38660123)
3. Sinha S, Gastineau D, Micallef I, Hogan W, Ansell S, Buadi F, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011;46:943-9.
4. + cells during leukapheresis procedures: relationship of volume processed and quantity of peripheral blood progenitor cells collected. Transfusion. 2000;40:493-5. (Pubitemid 30230518)
5. +) yield in patients going to autologous stem cell transplantation. J Clin Apher. 2006;21:92-5.
6. +) cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion. 2007;47:1851-7. (Pubitemid 47438552)
7. Delamain MT, Marques JFC Jr, De Souza CA, Lorand-Metze I, Metze K. An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fi xed CD34 threshold. Transfusion. 2008;48:1133-7. (Pubitemid 351793498)
8. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011;46:64-9.
9. +) cell numbers prior to leukapheresis: what should the threshold required for apheresis be. Bone Marrow Transplant 2008;42:439-42.
10. Chin-Yee I, Keeney M, Anderson L, Nayar R, Sutherland DR. Current status of CD34+ cell analysis by fl ow cytometry: the ISHAGE guidelines. Clin Immunol Newsletter. 1997;17:21-9.
11. Pineiro G, Perelman S, Guerschman JP, Paruelo JM. How to evaluate models: Observed vs. predicted or predicted vs. observed? Ecological Modelling 2008;216:316-22.
12. Meehan KR, Hill JM, Patchett L, Webber SM, Wu J, Ely P, et al. Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization. Transfusion. 2006;46:523-9.
13. Gertz, MA, Wolf RC, Micallef IN, Gastineau DA, et al. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010;45:1396-403.
14. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011;51:2175-82.